Originally published as JCO Early Release 10.1200/JCO.2005.00.398 on February 14 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tabernero, J. Articles by Baselga, J. Search for Related Content PubMed PubMed Citation Articles by Tabernero, J. Articles by Baselga, J. Social Bookmarking                            What's this?

Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Fredy Rojo, Irene Marimón, Maurizio Voi, Joan Albanell, Marta Guix, Federico Vázquez, Joan Carulla, Michael Cooper, Jordi Andreu, Anne Van Vreckem, Joaquim Bellmunt, Veeraswamy Manne, James A. Manning, Carmen Garrido, Enriqueta Felip, Josep Maria del Campo, Mónica García, Sonia Valverde, José Baselga

From the Departments of Medical Oncology, Pathology, and Radiology, Vall d'Hebron University Hospital, Barcelona, Spain; Bristol-Myers Squibb, Wallingford, CT, Waterloo, Belgium, and Madrid, Spain

Address reprint requests to Josep Tabernero, MD, Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron 119-129, Barcelona 08035, Spain; e-mail: jtabernero{at}vhebron.net.

PURPOSE: BMS-214662 is a potent, nonpeptide, small molecule inhibitor of human farnesyltransferase (FT). We have conducted a phase I pharmacokinetic (PK) and pharmacodynamic study of BMS-214662 administered intravenously weekly with 1- and 24-hour infusions. The objectives were to determine the dose-limiting toxicities and the recommended dose (RD), to describe PKs, and to evaluate the relationships between BMS-214662 exposure, FT inhibition, downstream signaling, and induction of apoptosis in tumor samples.

PATIENTS AND METHODS: Patients with advanced solid tumors and adequate organ function were eligible. The dose was escalated according to a modified Fibonacci schedule.

RESULTS: BMS-214662 was escalated from 56 to 278 mg/m² in 37 patients in the 1-hour schedule, and from 84 to 492 mg/m² in 31 patients in the 24-hour schedule. Dose-limiting toxicities included gastrointestinal and renal events. The RDs were 209 mg/m² and 275 mg/m² in the 1- and 24-hour schedules, respectively. Five patients (three with breast, one with gastric, and one with renal cell cancer) had clinical benefit from treatment. BMS-214662 exhibited linear PKs with area under the concentration-time curves at the RDs of 27 and 32 µM x h in the 1- and 24-hour schedules, respectively. The pattern of FT inhibition in peripheral-blood mononuclear cells at the RDs was different in the two schedules: high (> 80%) but short-lived ( 6 hours) in the 1-hour infusion and moderate (> 40%) but long-lived (24 hours) in the 24-hour infusion. BMS-214662 induced apoptosis in tumors but did not inhibit MAPK signaling.

CONCLUSION: BMS-214662 can be safely delivered in both the 1-hour and 24-hour infusions at biologically active doses, with the preclinical, PK, and pharmacodynamic profiles favoring the 24-hour schedule.

Presented in part at the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, Holland, November 7-10, 2000; at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001; and AACR-NCI-EORTC International Conference of Molecular Targets and Cancer Therapeutics, Miami, FL, October 29-November 2, 2001.

Terms in blue are defined in the glossary, found at the end of this issue and online at www.jco.org.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. Pellicano, M. Copland, H. G. Jorgensen, J. Mountford, B. Leber, and T. L. Holyoake BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase C{beta} Blood, November 5, 2009; 114(19): 4186 - 4196. [Abstract] [Full Text] [PDF]

				M. Copland, F. Pellicano, L. Richmond, E. K. Allan, A. Hamilton, F. Y. Lee, R. Weinmann, and T. L. Holyoake BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors Blood, March 1, 2008; 111(5): 2843 - 2853. [Abstract] [Full Text] [PDF]

				H. H. Bailey, D. B. Alberti, J. P. Thomas, D. L. Mulkerin, K. A. Binger, M. M. Gottardis, R. E. Martell, and G. Wilding Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors Clin. Cancer Res., June 15, 2007; 13(12): 3623 - 3629. [Abstract] [Full Text] [PDF]

				A. D. Basso, P. Kirschmeier, and W. R. Bishop Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors J. Lipid Res., January 1, 2006; 47(1): 15 - 31. [Abstract] [Full Text] [PDF]

				N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens Development of Farnesyl Transferase Inhibitors: A Review Oncologist, September 1, 2005; 10(8): 565 - 578. [Abstract] [Full Text] [PDF]

				J. Baselga and C. L. Arteaga Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459. [Abstract] [Full Text] [PDF]